Acute alveolitis following infliximab therapy for psoriasis

Bale, Jessica; Chee, Paul

doi:10.1111/j.1440-0960.2012.00924.x

Cited by 7 publications

(4 citation statements)

References 12 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several adverse reactions caused by biologic therapies have been reported 1,2 . Under anti‐TNF‐α therapies for psoriasis, interstitial lung disease (ILD) was reported as an adverse event 3,4 . Krebs von den Lungen‐6 (KL‐6), which is a human mucin 1 (MUC1) protein, is a mucinous sialylated sugar chain on MUC1 5 .…”

Section: Introductionmentioning

confidence: 99%

Serum Krebs von den Lungen‐6 levels in psoriatic patients under treatment with biologics

Iwata

Haga

Sugai

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

During biologic treatments, attention should be paid to adverse reactions, particularly infectious diseases. Furthermore, drug‐induced interstitial lung disease is also known to be associated with biologic therapies. We retrospectively reviewed serum Krebs von den Lungen‐6 (KL‐6) levels in psoriatic patients who underwent treatment with seven different biologics. A total of 67 patients who received 80 biologic treatments were evaluated. The 31 anti‐tumor necrosis factor (TNF)‐α treatments consisted of 17 infliximab (IFX) and 14 adalimumab. The 23 anti‐interleukin (IL)‐23 treatments consisted of 14 ustekinumab and nine guselkumab. The 26 anti‐IL‐17 treatments consisted of nine secukinumab, six ixekizumab and 11 brodalumab. The IFX showed significantly increased mean serum KL‐6 (170.9%), but none of the other treatments showed significant increases. Thirteen of the 17 (75.6%) patients in the IFX and 17 of the 31 (54.8%) patients in the total anti‐TNF‐α group demonstrated at least a 25% increase in serum KL‐6. Levels exceeding the cut‐off (500 U/mL) were detected in three patients before treatment and in seven patients after treatment. This study showed that anti‐IL‐17 and anti‐IL‐23 treatments have no significant impact on serum KL‐6 level. In addition to the influence of IFX, a significantly large number of patients in the IFX group had a history of methotrexate administration associated with psoriatic arthritis, which might have influenced the KL‐6 level. None of the patients with elevated serum KL‐6 showed pulmonary changes by computed tomography and/or X ray.

show abstract

Section: Introductionmentioning

confidence: 99%

Serum Krebs von den Lungen‐6 levels in psoriatic patients under treatment with biologics

Iwata

Haga

Sugai

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…We searched the English literature using PubMed, and found only five case reports of ILD induced by biologic agents in patients with psoriasis outside Japan 2,16–19 . All cases were associated with IFX, with severe respiratory symptoms that required systemic treatment.…”

Section: Discussionmentioning

confidence: 99%

“…We searched the English literature using PubMed, and found only five case reports of ILD induced by biologic agents in patients with psoriasis outside Japan. 2,[16][17][18][19] All cases were associated with IFX, with severe respiratory symptoms that required systemic treatment. It is notable that most Japanese cases had mild symptoms and recovered after cessation of the drug without any specific treatment for ILD.…”

Section: Discussionmentioning

confidence: 99%

The risk of interstitial lung disease during biological treatment in Japanese patients with psoriasis

et al. 2020

View full text Add to dashboard Cite

Summary Background With the increasing use of biological agents for the treatment of psoriasis, the numbers of patients with interstitial lung disease (ILD) associated with biologics have also increased. Many of these cases were associated with tumour necrosis factor (TNF)‐α inhibitors, but cases associated with other families of biologics have also been reported in Japan. Aim To analyse the background factors of patients who developed ILD, and to discuss better management of biological treatment. Method We reviewed 246 patients with psoriasis who were treated with biological agents in our department to identify any pulmonary adverse events (AEs). Data on patients who developed ILD were extracted to analyse background factors, clinical type of psoriasis, time to onset of ILD, pre‐existing ILD, smoking habit and prescribed drugs. Results Pulmonary AEs were seen in 22 cases, of which 11 were diagnosed as drug‐induced ILD. The causative drugs were mainly TNF‐α inhibitors, accounting for eight cases (six treated with infliximab, two with adalimumab). The remaining three cases were associated with secukinumab, ustekinumab and ixekizumab (n = 1 each). Notably, these three cases also had a history of drug‐induced ILD. Conclusion Patients with a history of drug‐induced ILD seem to be more susceptible to developing another ILD induced by biologics, even if treated with interleukin‐17 inhibitors. Thorough screening of risk factors and evaluation for eligibility, and careful monitoring during treatment are the best solutions to avoid serious pulmonary AE. Early detection and precise diagnosis of pulmonary AEs, especially differentiation from infectious diseases, is essential for managing biological treatment.

show abstract

“…This was probably because of the effects of both AS and Anti‐TNF treatment. In addition to relieving AS symptoms, these drugs may cause pulmonary parenchymal or airway changes . However, there are few reports in the literature.…”

Section: Discussionmentioning

confidence: 99%

Relationship of CTLA4 and CD28 polymorphisms with lung involvement, HRCT findings and pulmonary function tests in Turkish patients with ankylosing spondylitis

Okyaltirik

Rezvanı

Turan

et al. 2015

Clinical Respiratory J

View full text Add to dashboard Cite

show abstract

Acute alveolitis following infliximab therapy for psoriasis

Cited by 7 publications

References 12 publications

Serum Krebs von den Lungen‐6 levels in psoriatic patients under treatment with biologics

Serum Krebs von den Lungen‐6 levels in psoriatic patients under treatment with biologics

The risk of interstitial lung disease during biological treatment in Japanese patients with psoriasis

Relationship of CTLA4 and CD28 polymorphisms with lung involvement, HRCT findings and pulmonary function tests in Turkish patients with ankylosing spondylitis

Contact Info

Product

Resources

About